News

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that its partner, Gaelan Medical LLC, a wholly owned subsidiary of the Ghassan Aboud Group (GAG), has received…
Read More...

Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, announced the closing of an oversubscribed $31…
Read More...

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer…
Read More...

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations,…
Read More...

AbbVie and Calibr announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or…
Read More...

InSilicoTrials, a leading provider of artificial intelligence (AI) and simulation tools for drug and medical device development, has embarked on a collaborative partnership with Axoltis…
Read More...

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced the initiation…
Read More...

Ayala Pharmaceuticals, Inc. and Biosight Ltd. announced they have entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock…
Read More...

Kriya Therapeutics, Inc. announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million.…
Read More...

LianBio’s partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotlilaner ophthalmic solution) 0.25% for the…
Read More...

The European Commission (EC) approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced.…
Read More...

Astellas Pharma Inc. and PeptiDream Inc. announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. Under the…
Read More...

Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., a global leader in generic and innovative medicines and Alvotech, a global biotech company…
Read More...

Sandoz announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorization for…
Read More...

ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company…
Read More...

Cognizant announced an expansion of its relationship with Gilead Sciences. Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat…
Read More...

Alnylam Pharmaceuticals, Inc. announced it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the…
Read More...

Daiichi Sankyo announced that VANFLYTA (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in combination with standard cytarabine and anthracycline induction…
Read More...

Ipsen announced that the European Commission has followed guidance provided by the Committee for Medicinal Products for Human Use (CHMP) in May this year, and has not granted marketing…
Read More...